INS and type 2 diabetes mellitus: Glucagon secretion is observed to be reduced in patients with T1DM, with an increasing risk of insulin-induced hypoglycemia, but it is enhanced in T2DM, exacerbating the effects of reduced insulin release and action on glucose of blood levels (Gromada et al., 2018).